Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nanjing Leads Biolabs CoFRA:0DX -3.38%19 Debt-to-Equity is 0.22 as of Dec. 2025, which is at its 10-year median of 0.22. GuruFocus rates FRA:0DX with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 954 Biotechnology companies, Nanjing Leads Biolabs Co ranks worse than 57.02% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Nanjing Leads Biolabs Co's Debt-to-Equity or its related term are showing as below:
FRA:0DX'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.07 Med: 0.22 Max: 1
Current: 0.22
During the past 3 years, the highest Debt-to-Equity Ratio of Nanjing Leads Biolabs Co was 1.00. The lowest was -0.07. And the median was 0.22.
FRA:0DX's Debt-to-Equity is ranked worse than 57.02% of 954
companies
in the Biotechnology industry
Industry Median: 0.16
vs FRA:0DX: 0.22
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Nanjing Leads Biolabs Co Debt-to-Equity Related Terms
Nanjing Leads Biolabs Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Leads Biolabs Co Debt-to-Equity Chart
Nanjing Leads Biolabs Co Annual Data
Trend
Dec23
Dec24
Dec25
Debt-to-Equity
-0.07
1.00
0.22
Nanjing Leads Biolabs Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Debt-to-Equity
-0.07
N/A
1.00
2.86
0.22
FRA:0DX vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Nanjing Leads Biolabs Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing Leads Biolabs Co Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanjing Leads Biolabs Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Nanjing Leads Biolabs Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Leads Biolabs Co (FRA:0DX) has a Debt-to-Equity of 0.22 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nanjing Leads Biolabs Co and its competitors. This is near median its historical median of 0.22. According to the industry distribution chart, Nanjing Leads Biolabs Co ranks #544 out of 954 companies in the Biotechnology industry, placing it in the top 57%.
Is Nanjing Leads Biolabs Co's Debt-to-Equity too high?
Nanjing Leads Biolabs Co's current Debt-to-Equity of 0.22 is near median its 10-year median of 0.22. The Biotechnology industry median Debt-to-Equity is 0.16. Nanjing Leads Biolabs Co's value of 0.22 is 37.5% above this industry median. Based on the distribution chart, Nanjing Leads Biolabs Co ranks #544 out of 954 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nanjing Leads Biolabs Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Nanjing Leads Biolabs Co's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanjing Leads Biolabs Co ranks #544 out of 954 companies for Debt-to-Equity. This places Nanjing Leads Biolabs Co in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Nanjing Leads Biolabs Co's value of 0.22 is 37.5% above this benchmark. While the company's 10-year median is 0.22 vs. the industry median of 0.16, Nanjing Leads Biolabs Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanjing Leads Biolabs Co's current Debt-to-Equity of 0.22 is 37.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nanjing Leads Biolabs Co and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanjing Leads Biolabs Co's current Debt-to-Equity is 0.22, which is near median its own 10-year median of 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Leads Biolabs Co stock overvalued right now?
Nanjing Leads Biolabs Co (FRA:0DX) has a current Debt-to-Equity of 0.22. The current Debt-to-Equity is 0.22, which is near median its 10-year median of 0.22 and 37.5% above the Biotechnology industry median of 0.16. Nanjing Leads Biolabs Co's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Nanjing Leads Biolabs Co (FRA:0DX), the current Debt-to-Equity is 0.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nanjing Leads Biolabs Co Ltd is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Group uses its science-driven R&D approach and three proprietary technology platforms: X-body (4-1BB Engager), LeadsBody (CD3 T Cell Engager), and TOPiKinectics (ADC), for its multi-modal, differentiated pipeline in oncology and autoimmune diseases. It has approximately fourteen drug candidates across oncology and autoimmune diseases. Among these, one core product (LBL-024, a pivotal-stage PD-L1 and 4-1BB dual-targeting bispecific antibody) is being evaluated in several cancer indications and across various Proof-of-Concept (POC) studies. The Group generates maximum revenue from the USA.
19GF Score
Get the complete analysis for FRA:0DX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0DX has been successfully added to your 
